Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Michael G. Hanna, Umesh A. Badrising, Olivier Benveniste, Thomas E. Lloyd, Merrilee Needham, Hector Chinoy, Masashi Aoki, Pedro M. Machado, Christina Liang, Katrina A. Reardon, Marianne de Visser, Dana P. Ascherman, Richard J. Barohn, Mazen M. Dimachkie, James A.L. Miller, John T. Kissel, Björn Oskarsson, Nanette C. Joyce, P. Van den Bergh, Jonathan BaetsJ. L. De Bleecker, Chafic Karam, William S. David, Massimiliano Mirabella, Sharon P. Nations, Hans H. Jung, E. Pegoraro, Lorenzo Maggi, Carmelo Rodolico, Massimiliano Filosto, Aziz I. Shaibani, Kumaraswamy Sivakumar, Namita A. Goyal, Madoka Mori-Yoshimura, Satoshi Yamashita, N. Suzuki, Masahisa Katsuno, K. Murata, Hiroyuki Nodera, Ichizo Nishino, Carla D. Romano, Valerie S.L. Williams, John Vissing, Lixin Zhang Auberson, Min Wu, Ana de Vera, Dimitris A. Papanicolaou, Anthony A. Amato
Dive into the research topics of 'Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial'. Together they form a unique fingerprint.